Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress

12 hours ago 1

Jonathan Ponciano, The Motley Fool

Sat, February 14, 2026 astatine 10:18 AM CST 4 min read

On February 13, 2026, Affinity Asset Advisors disclosed a caller presumption successful Praxis Precision Medicines (NASDAQ:PRAX), acquiring 185,000 shares successful an estimated $54.53 cardinal trade.

According to a SEC filing dated February 13, 2026, Affinity Asset Advisors, LLC reported a caller presumption successful Praxis Precision Medicines (NASDAQ:PRAX), acquiring 185,000 shares during the 4th quarter. The quarter-end worth of the presumption registered arsenic $54.53 million, reflecting the combined interaction of the stock acquisition and consequent marketplace terms changes.

The PRAX involvement represents a caller position, present accounting for 3.11% of the fund’s 13F reportable assets.
Top 5 money holdings aft the filing:
- NASDAQ: APGE: $93.21 cardinal (6.9% of AUM)
- NASDAQ: INSM: $78.32 cardinal (5.8% of AUM)
- NASDAQ: ABVX: $68.10 cardinal (5.0% of AUM)
- NASDAQ: VTYX: $58.56 cardinal (4.3% of AUM)
- NASDAQ: XENE: $56.02 cardinal (4.1% of AUM)
As of February 13, 2026, shares of Praxis Precision Medicines were priced astatine $317.25, up 266.1% implicit the past twelvemonth and vastly outperforming the S&P 500 by 254.29 percent points.

Metric

Value

Price (as of marketplace adjacent February 13, 2026)	$317.25
Market capitalization	$8.8 billion
Revenue (TTM)	$7.46 million
Net income (TTM)	($273.04 million)

Praxis Precision Medicines develops clinical-stage therapies for cardinal tense strategy disorders, with pb candidates including PRAX-114 (major depressive disorder), PRAX-944 (essential tremor), PRAX-562 (epilepsy and cephalgia), and antisense oligonucleotide programs targeting uncommon epilepsies.
It’s a Boston-based biotechnology institution specializing successful caller therapies for neurological and psychiatric conditions characterized by neuronal imbalance.
The steadfast leverages a robust objective pipeline and strategical collaborations to code important gaps successful neurological and psychiatric care.

Praxis Precision Medicines focuses connected innovative tiny molecules and antisense oligonucleotides, positioning itself to perchance present first-in-class treatments for analyzable neurological conditions. Its strategical attack aims to code unmet needs successful cardinal tense strategy disorders.

Praxis is successful the mediate of 1 of the astir consequential periods successful its history. In January, the steadfast said it expects 2 caller cause exertion submissions by mid-February for ulixacaltamide and relutrigine, with CEO Marcio Souza saying some “delivered compelling late-stage results and earned Breakthrough Therapy Designation.” In the firm’s latest net release, absorption highlighted pro forma currency and investments of astir $956 million, including proceeds from an October offering, which are expected to money operations into 2028. That benignant of runway meaningfully reduces near-term financing risk.

Third-quarter probe and improvement disbursal roseate to $65.8 million, and nett nonaccomplishment widened to $73.9 million. This is inactive a clinical-stage biotech, and volatility is the terms of admission. But the portfolio present spans aggregate late-stage and registrational programs, including relutrigine and vormatrigine, creating respective shots connected goal.

For a money already concentrated successful high-conviction biotech names, adding present aft a 266% one-year determination signals content that the communicative is shifting from committedness to imaginable commercialization. Ultimately, semipermanent investors should absorption little connected the caller stock surge and much connected regulatory milestones, currency discipline, and execution this year.

Read Entire Article